OBJECTIVE: There are limited data about the effects of sodium glucose cotransporter 2 inhibitors when used with insulin. We report the efficacy and safety of canagliflozin in patients with type 2 diabetes using insulin.
RESEARCH DESIGN AND METHODS: The Canagliflozin Cardiovascular Assessment Study is a double-blind, placebo-controlled study that randomized participants to placebo, canagliflozin 100 mg, or canagliflozin 300 mg once daily, added to a range of therapies. The primary end point of this substudy was the change in HbA1c from baseline at 18 weeks among patients using insulin; 52-week effects were also examined.
READ FULL ARTICLE From Diabetesjournals